All In Biotech

Drug Trial Radar · NCT03894046

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Last checked: Nov 20, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

207

Actual

Start

Sep 5, 2019

Primary completion

Jul 26, 2021

Study completion Jul 26, 2021

Sponsor

Lead sponsor
Entasis TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part study, with Part A being the randomized, controlled portion of the study in patients with ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or bacteremia. Part B is the single-group portion of the study and includes ABC infections that are resistant to or have failed colistin or polymyxin B treatment, as detailed in the inclusion criteria.

Conditions

  • Acinetobacter Baumannii-calcoaceticus Complex
  • Hospital-acquired Bacterial Pneumonia
  • Ventilator-associated Bacterial Pneumonia
  • Bacteremia
  • Colistin Resistant ABC

Interventions

  • SulbactamDrug

    1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).

  • DurlobactamDrug

    1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h). Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated.

  • ColistinDrug

    Treatment for 7 days up to 14 days if clinically indicated.

  • Imipenem/Cilastatin 500 mg/500 mgDrug

    1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With All-Cause Mortality in CRABC m-MITT PopulationTime frame: 28 Days
  2. Proportion of Patients With NephrotoxicityTime frame: 28 days

Locations

90 sites in 17 countries. Site status is shown where the registry gives one.

  • Entasis Research Site

    Chicago, Illinois

  • Entasis Research Site

    Shreveport, Louisiana

  • Entasis Research Site

    Cincinnati, Ohio

  • Entasis Research Site

    Memphis, Tennessee

  • Entasis Research Site

    Houston, Texas

  • Entasis Research Site

    Brest, Belarus

  • Entasis Research Site

    Grodno, Belarus

  • Entasis Research Site

    Homyel, Belarus

  • Entasis Research Site

    Minsk, Belarus

  • Entasis Research Site

    Belo Horizonte, Brazil

  • Entasis Research Site

    Campinas, Brazil

  • Entasis Research Site

    Porto Alegre, Brazil

  • Entasis Research Site

    Salvador, Brazil

  • Entasis Research Site

    São José do Rio Preto, Brazil

  • Entasis Research Site 1

    Beijing, China

  • Entasis Research Site 2

    Beijing, China

  • Entasis Research Site 3

    Beijing, China

  • Entasis Research Site

    Changsha, China

  • Entasis Research Site

    Chongqing, China

  • Entasis Research Site

    Guangzhou, China

  • Entasis Research Site

    Hebei, China

  • Entasis Research Site 1

    Hefei, China

  • Entasis Research Site 2

    Hefei, China

  • Entasis Research Site

    Hubei, China

  • Entasis Research Site

    Nanchang, China

  • Entasis Research Site

    Nanjing, China

  • Entasis Research Site

    Nanning, China

  • Entasis Research Site 1

    Shanghai, China

  • Entasis Research Site 2

    Shanghai, China

  • Entasis Research Site

    Shenzhen, China

  • Entasis Research Site

    Tianjin, China

  • Entasis Research Site

    Wuhan, China

  • Entasis Research Site 1

    Athens, Greece

  • Entasis Research Site 3

    Athens, Greece

  • Entasis Research Site

    Heraklion, Greece

  • Entasis Research Site

    Larissa, Greece

  • Entasis Research Site

    Thessaloniki, Greece

  • Entasis Research Site 1

    Budapest, Hungary

  • Entasis Research Site 2

    Budapest, Hungary

  • Entasis Research Site

    Debrecen, Hungary

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.